Front Row Advisors LLC Intra Cellular Therapies, Inc. Transaction History

Front Row Advisors LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 15, 2024	SELL	$64.76 - $79.84 $2,331 - $2,874	-36 Reduced 27.07%	97 $6,000
Q1 2024 May 14, 2024	BUY	$64.37 - $75.65 $8,561 - $10,061	133 New	133 $9,000
Q3 2023 Nov 15, 2023	BUY	$52.09 - $64.1 $468 - $576	9 Added 8.33%	117 $6,000
Q1 2023 May 22, 2023	BUY	$43.8 - $56.99 $4,467 - $5,812	102 Added 1700.0%	108 $6,000
Q1 2023 May 15, 2023	SELL	$43.8 - $56.99 $3,460 - $4,502	-79 Reduced 92.94%	6 $11,000
Q3 2022 Nov 15, 2022	BUY	$42.7 - $59.99 $3,629 - $5,099	85 New	85 $4,000

378

84.7M

319K

143K

Ticker ITCI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 94,401,696
Market Cap $7.85B
Description
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...

Get notified when there are updates to the investment portfolio of Front Row Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Front Row Advisors LLC with notifications on news.